Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual.
Kim YeohCornelia Lass-FlörlFrederic LamothMonica A SlavinEloise WilliamsDionysios NeofytosPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2024)
This case involves a 53-year-old female with concurrent acute myeloid leukemia (AML) and multiple myeloma. She underwent cytarabine and daunorubicin (7+3) induction chemotherapy followed by cytarabine (HiDAC) consolidation, with an early AML relapse requiring azacitidine and venetoclax therapy. She achieved complete remission and incomplete count recovery. Following fludarabine, melphalan, and thymoglobulin induction chemotherapy, she underwent an allogeneic stem cell transplant with failure to engraft, requiring autologous stem cell rescue, buffy coat, and granulocyte transfusions, eventually presenting with a diffuse skin rash consistent with Steven-Johnson syndrome and toxic epidermal necrolysis, persistent neutropenic fevers and positive blood cultures.
Keyphrases
- acute myeloid leukemia
- stem cells
- cell therapy
- stem cell transplantation
- locally advanced
- bone marrow
- high dose
- multiple myeloma
- allogeneic hematopoietic stem cell transplantation
- peripheral blood
- hematopoietic stem cell
- case report
- rectal cancer
- wound healing
- single cell
- squamous cell carcinoma
- low dose
- low grade
- soft tissue
- mesenchymal stem cells
- ulcerative colitis
- escherichia coli
- disease activity
- acute lymphoblastic leukemia
- chronic lymphocytic leukemia
- high grade